Tirzepatide denied as not FDA-approved for this use by Anthem?
Off-label use is widespread in medicine. If the literature and a recognised specialty-society guideline support the use, plans frequently approve on appeal — especially for cancer, cardiology, and rare disease.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Anthem typically requires
Anthem's specific coverage criteria for tirzepatide are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.
The Anthem angle on Tirzepatide
## Why Anthem Issues a "Not FDA-Approved" Denial for Tirzepatide
This denial reason typically arises in one of two situations: (1) the prescriber has requested tirzepatide for an indication that is not listed in the FDA-approved label — commonly called off-label use — or (2) Anthem's system has applied the denial in error when the requested indication is, in fact, FDA-approved. Both situations are appealable, but the strategy differs significantly.
Tirzepatide has received FDA approval for specific indications. Before appealing, confirm with your prescriber which indication is being prescribed and whether it matches an approved label indication. If the use is off-label, the appeal must be built on evidence-based clinical support rather than label alignment alone.
## Your Federal Appeal Rights
- ACA §2719 / External Review: For plans subject to the ACA, you may request IRO external review after exhausting internal appeals. The external-review window is typically around four months from the final internal denial — verify the exact date on your denial letter.
- ERISA §503 Full-and-Fair Review: ERISA plans must disclose the specific clinical criteria and evidence standards used to deny off-label requests, and must consider submitted peer-reviewed evidence.
- Expedited Review: Available when the clinical situation is urgent; request it in writing at the same time as the standard appeal.
## Appeal Strategy: On-Label vs. Off-Label
If the use is on-label: The denial is likely administrative error. Your appeal should attach the current FDA-approved prescribing information (package insert) and a cover letter from the prescriber affirming the specific approved indication being treated. Request correction without full clinical review.
If the use is off-label: The appeal must demonstrate substantial clinical evidence. Gather peer-reviewed published literature supporting the use, relevant professional society position statements, and a detailed prescriber letter explaining why this use is consistent with accepted medical practice for this patient.
## Documentation to Gather
- Current FDA prescribing information for tirzepatide (available at DailyMed), with the applicable indication highlighted.
- Prescriber attestation confirming the indication being treated and its alignment with the label (or, for off-label, citing the evidentiary basis).
- Diagnosis documentation: Chart notes, lab results, and specialist records confirming the diagnosis.
- For off-label appeals: Published peer-reviewed literature, professional society guidelines or consensus statements supporting the use.
- Prior treatment history: Documented trial of labeled alternatives if applicable.
## Criteria-Mapping Structure
Pull Anthem's published clinical policy for tirzepatide and its off-label drug use policy. For each listed requirement — whether an approved compendia citation, peer-review standard, or medical-necessity criterion — provide a specific responsive document. A point-by-point mapping, with each Anthem requirement answered by a named exhibit, is the most defensible appeal format.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →